Cancer patients who suffer from pulmonary embolism face an elevated risk of VTE recurrence, particularly those with pancreatic cancer, hematologic cancers, lung cancer, stomach cancer, and brain cancer, warranting extended anticoagulant therapy, ideally with LMWH or DOACs instead of VKAs.